OPERA-01 Phase 3 study is for people with advanced and/or metastatic ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitors and endocrine therapy.

Breast cancer impacts millions of patients, families, and loved ones worldwide. For many, who develop metastatic disease, this complex and difficult journey is even more taxing.

Palazestrant (OP-1250), our lead candidate, is a once-daily oral medicine with best-in-class potential for metastatic breast cancer.

OPERA-01 Phase 3 study is for people with advanced and/or metastatic ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitors and endocrine therapy.

Breast cancer impacts millions of patients, families, and loved ones worldwide. For many, who develop metastatic disease, this complex and difficult journey is even more taxing.